Product Images Tamsulosin Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Tamsulosin Hydrochloride NDC 70934-092 by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
70934 092 30 Master Bottle Label Approval Rev B 04 19
The text describes a medication with the NDC code of 70934.092-30. The medication is Tamsulosin Hydrochloride and is available in the form of Capsules, USP with a strength of 0.4mg.*
Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1
This appears to be a graphical representation of the mean plasma concentrations of Tamsulosin Hydrochloride Capsules 0.4 mg under both fasted and fed conditions. The horizontal axis displays the time in hours and the vertical axis shows the concentration levels.*
Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2
The figure shows the mean change from baseline in the total AUA Symptom Score for Study 1. The x-axis displays the duration of treatment in weeks, while the y-axis shows the mean change. There are two treatment groups: the first received 0.4mg AFLUZOsin and the second group received a placebo. The plot also includes the number of subjects in each treatment group at each time point.*
Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3
This is a graph showing the mean change from baseline in Total AUA Symptom Score in Study 2, with three different treatments: O=0O—0-08mg LNt, 0.4mg, and Placebo. The x-axis represents the duration of treatment in weeks, and the y-axis represents the mean change. There are data points at weeks 0, 1, 2, 5, 9, 13, and LOCF.*
Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4
This is a figure that shows the mean increase in peak urine flow rate in mL/sec for Study 1. The treatment group is divided into three sub-groups; the first received 0.08mg, the second received 0.4mg twice, and the third received a placebo. The y-axis shows the mean change in mL/sec and the x-axis shows the duration of treatment in weeks. The data is based on a sample of 635, 621, and 617 individuals for each of the treatment groups respectively, and 755, 752, 713, and 694 individuals for each of the corresponding placebo groups.*
Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5
This text appears to be a part of a scientific study or research paper. It includes a figure titled "Figure 3B" which shows the mean increase in peak urine flow rate in mL/Sec over the course of a treatment identified as "Study 2." The figure presents data points on a graph corresponding to different treatment durations in weeks, ranging from 0 to 20. Unfortunately, no additional information is provided to understand the context or purpose of this study.*
Chemical Structure - tamsulosin str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.